Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016

Date: May 31, 2016
Pages: 1047
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HDC65846266EN
Leaflet:

Download PDF Leaflet

Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016

SUMMARY

GlobalData's clinical trial report, “Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016' provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Hepatocellular Carcinoma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Hepatocellular Carcinoma
May 19, 2016: Incyte Highlights Capmatinib Abstracts to be Presented at the 2016 ASCO Annual Meeting
May 18, 2016: Eli Lilly to Present data on VEGF Receptor 2 antagonist ramucirumab at ASCO
May 18, 2016: Lilly to present data on TGFß small-molecule kinase inhibitor galunisertib at ASCO
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)
May 04, 2016: RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA Phase II Hepatocellular Carcinoma Study
May 04, 2016: Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival
Apr 26, 2016: Celsion Announces Enrollment of First Patient in the OPTIMA Study in China
Apr 18, 2016: Onxeo Final Data from Mechanistic Livatag Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment
Apr 15, 2016: Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
Apr 04, 2016: Onxeo announces positive DSMB recommendation to continue Livatag ReLive study in HCC
Mar 29, 2016: SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
Mar 22, 2016: Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma
Mar 16, 2016: Onxeo Poster Demonstrating Unique Livatag Mechanism of Action Accepted for Presentation at AACR Annual Meeting
Mar 07, 2016: Major Liver Cancer Study Completes Palliative Cohort Enrolment
Mar 07, 2016: Celsion Announces Launch of the OPTIMA Study in China
Clinical Trial Profile Snapshots
Appendix 1044
Abbreviations 1044
Definitions 1044
Research Methodology 1045
Secondary Research 1045
About GlobalData 1046
Contact Us 1046
Disclaimer 1046
Source 1047

LIST OF TABLES

Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Region, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016
Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016
Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016
Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Hepatocellular Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016

LIST OF FIGURES

Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016
Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016
Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016
Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Hepatocellular Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016
GlobalData Methodology 1045

COMPANIES MENTIONED

Bayer AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Eli Lilly and Company
AstraZeneca Plc
Bristol-Myers Squibb Company
Otsuka Holdings Co., Ltd.
Amgen Inc.
Eisai Co., Ltd.
Skip to top


Ask Your Question

Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: